Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: Impact on clinicopathological features and disease recurrence

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1286-1294

  Eissa, Sanaa ^a   Zohny, Samir F ^b   Zekri, Abdel Rahman N ^c   El Zayat, Tarek Mostafa ^d   Maher, Amany M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Ain Shams University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bladder cancer; Fibronectin; Mutant p53; Urine cytology

Indexed keywords

FIBRONECTIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINE; URINE CYTOLOGY;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYSTOSCOPY; FEMALE; FIBRONECTINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; ROC CURVE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 79951774687     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9375-9     Document Type: Article

References (26)

1. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25:285-95.
2. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta. 2004;340:57-65. (Pubitemid 38167508)
3. Eissa S, Zohny SF, Swellam M, Mahmoud MH, El-Zayat TM, Salem AM. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem. 2008;41:1335-41.
4. Mao Y, Schwarzbauer JE. Fibronectin fibrillogenesis, a cellmediated matrix assembly process. Matrix Biol. 2005;24:389-99. (Pubitemid 41765018)
5. Kirkali G, Tuzel E, Guler C, Gezer S, Kirkali Z. Significance of tissue laminin P (1) elastase and fibronectin levels in transitional cell carcinoma of the bladder. Eur Urol. 2001;39:292-9. (Pubitemid 32245369)
6. Youssef RF, Mitra AP, Bartsch G, Jones PA, Skinner DG, Cote RJ. Molecular targets and targeted therapies in bladder cancer management. World J Urol. 2009;27:9-20.
7. Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002;8:171-9. (Pubitemid 34101474)
8. Schroeder JC, Conway K, Li Y, Mistry K, Bell DA, Taylor JA. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res. 2003;63:7530-8. (Pubitemid 37413499)
9. Khaled HM, Bahnassi AA, Zekri A-RN, Kassem AH, Mokhtar N. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol. 2003;21:334-41. (Pubitemid 38534172)
10. Prescott JL, Montie J, Pugh TW, McHugh T, Veltri RW. Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer. 2001;91:2127-35. (Pubitemid 32476378)
11. Schlichtholz B, Presler M, Matuszewski M. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast. Carcinogenesis. 2004;25:2319-23. (Pubitemid 39625171)
12. American Joint Committee on Cancer (AJCC). Cancer staging manual. 5th ed. Lippincott-Raven: Philadelphia; 1997. p. 241.
13. Sobin LH, Wittkind CH. UICC TNM classification of malignant tumors. 5th ed. ed. New York: Wiley Liss; 1997. p. 187.
14. Eissa S, Labib RA, Mourad MS, Kamel K, El-Ahmady O. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. Eur Urol. 2003;44:687-94. (Pubitemid 37542927)
15. Gui M, Idris MA, Shi YE, Muhling A, Ruppel A. Reactivity of Schistosoma japonicum and S. mansoni antigen preparations in indirect haemagglutination (IHA) with sera of patients with homologous and heterologous schistosomiasis. Ann Trop Med Parasitol. 1991;85:599-604.
16. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 1945;101:519-20.
17. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989. p. 42-59.
18. Phillips HA, Howard GCW, Miller WR. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. Br J Cancer. 2000;82:136-41. (Pubitemid 30008972)
19. Wang H, Chen XP, Qiu FZ. Overcoming multi-drug resistance by anti-MDR1 ribozyme. World J Gastroenterol. 2003;9:1444-9. (Pubitemid 36992330)
20. Bharaj BS, Angelopoulou K, Diamandis EP. Rapid sequencing of the p53 gene with a new automated DNA sequencer. Clin Chem. 1998;44:1397-403. (Pubitemid 28309097)
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36. (Pubitemid 12142173)
22. Cox DR, Oakes D. Analysis of survival data. London: Chapmann and Hall; 1984.
23. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol. 2002;168:465-9. (Pubitemid 34793273)
24. Menendez V, Fernandez-Suarez A, Galan JA, Perez M, Garcia-Lopez F. Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology. 2005;65:284-9. (Pubitemid 40248014)
25. Katayama M, Kamihagi K, Nakagawa K, Akiyama T, Sano Y, Ouchi R, et al. Increased fragmentation of urinary fibronectin in cancer patients detected by immunoenzymometric assay using domain-specific monoclonal antibodies. Clin Chim Acta. 1993;217:115-28. (Pubitemid 23274402)
26. Velculesu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem. 1996;42:858-68.